Logo image of AHR

AMERICAN HEALTHCARE REIT INC (AHR) Stock Fundamental Analysis

NYSE:AHR - New York Stock Exchange, Inc. - US3981823038 - REIT - Currency: USD

31.11  +0.03 (+0.1%)

After market: 31.11 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to AHR. AHR was compared to 130 industry peers in the Diversified REITs industry. AHR has a bad profitability rating. Also its financial health evaluation is rather negative. AHR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year AHR has reported negative net income.
AHR had a positive operating cash flow in the past year.
AHR Yearly Net Income VS EBIT VS OCF VS FCFAHR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

The Return On Assets of AHR (-0.84%) is worse than 67.69% of its industry peers.
AHR has a worse Return On Equity (-1.67%) than 66.92% of its industry peers.
With a Return On Invested Capital value of 2.66%, AHR perfoms like the industry average, outperforming 52.31% of the companies in the same industry.
AHR had an Average Return On Invested Capital over the past 3 years of 1.94%. This is in line with the industry average of 3.17%.
The 3 year average ROIC (1.94%) for AHR is below the current ROIC(2.66%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA -0.84%
ROE -1.67%
ROIC 2.66%
ROA(3y)-1.37%
ROA(5y)N/A
ROE(3y)-4.37%
ROE(5y)N/A
ROIC(3y)1.94%
ROIC(5y)N/A
AHR Yearly ROA, ROE, ROICAHR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 2 -2 -4

1.3 Margins

AHR has a worse Operating Margin (6.61%) than 82.31% of its industry peers.
AHR's Operating Margin has improved in the last couple of years.
The Gross Margin of AHR (20.13%) is worse than 92.31% of its industry peers.
In the last couple of years the Gross Margin of AHR has remained more or less at the same level.
Industry RankSector Rank
OM 6.61%
PM (TTM) N/A
GM 20.13%
OM growth 3Y31.86%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.79%
GM growth 5YN/A
AHR Yearly Profit, Operating, Gross MarginsAHR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 5 10 15 20

More info and screens

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so AHR is destroying value.
Compared to 1 year ago, AHR has more shares outstanding
The debt/assets ratio for AHR has been reduced compared to a year ago.
AHR Yearly Shares OutstandingAHR Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 50M 100M 150M
AHR Yearly Total Debt VS Total AssetsAHR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

Based on the Altman-Z score of 1.40, we must say that AHR is in the distress zone and has some risk of bankruptcy.
AHR's Altman-Z score of 1.40 is amongst the best of the industry. AHR outperforms 89.23% of its industry peers.
AHR has a debt to FCF ratio of 71.67. This is a negative value and a sign of low solvency as AHR would need 71.67 years to pay back of all of its debts.
AHR has a Debt to FCF ratio (71.67) which is in line with its industry peers.
AHR has a Debt/Equity ratio of 0.75. This is a neutral value indicating AHR is somewhat dependend on debt financing.
AHR has a better Debt to Equity ratio (0.75) than 73.08% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.75
Debt/FCF 71.67
Altman-Z 1.4
ROIC/WACC0.35
WACC7.53%
AHR Yearly LT Debt VS Equity VS FCFAHR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

AHR has a Current Ratio of 0.68. This is a bad value and indicates that AHR is not financially healthy enough and could expect problems in meeting its short term obligations.
AHR's Current ratio of 0.68 is on the low side compared to the rest of the industry. AHR is outperformed by 66.92% of its industry peers.
AHR has a Quick Ratio of 0.68. This is a bad value and indicates that AHR is not financially healthy enough and could expect problems in meeting its short term obligations.
AHR has a Quick ratio of 0.68. This is in the lower half of the industry: AHR underperforms 66.15% of its industry peers.
Industry RankSector Rank
Current Ratio 0.68
Quick Ratio 0.68
AHR Yearly Current Assets VS Current LiabilitesAHR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

AHR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 73.26%, which is quite impressive.
The Revenue has grown by 10.93% in the past year. This is quite good.
The Revenue has been growing by 17.32% on average over the past years. This is quite good.
EPS 1Y (TTM)73.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.78%
Revenue 1Y (TTM)10.93%
Revenue growth 3Y17.32%
Revenue growth 5YN/A
Sales Q2Q%12.47%

3.2 Future

Based on estimates for the next years, AHR will show a very strong growth in Earnings Per Share. The EPS will grow by 70.49% on average per year.
Based on estimates for the next years, AHR will show a quite strong growth in Revenue. The Revenue will grow by 9.72% on average per year.
EPS Next Y236.54%
EPS Next 2Y101.89%
EPS Next 3Y70.49%
EPS Next 5YN/A
Revenue Next Year8.62%
Revenue Next 2Y7.49%
Revenue Next 3Y9.72%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AHR Yearly Revenue VS EstimatesAHR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B 2B 2.5B
AHR Yearly EPS VS EstimatesAHR Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 0 0.5 -0.5

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AHR. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 84.39, the valuation of AHR can be described as expensive.
AHR's Price/Forward Earnings is on the same level as the industry average.
AHR is valuated expensively when we compare the Price/Forward Earnings ratio to 21.38, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 84.39
AHR Price Earnings VS Forward Price EarningsAHR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 100 -100

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AHR indicates a rather expensive valuation: AHR more expensive than 83.85% of the companies listed in the same industry.
AHR's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 207.47
EV/EBITDA 20.76
AHR Per share dataAHR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

AHR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as AHR's earnings are expected to grow with 70.49% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y101.89%
EPS Next 3Y70.49%

More info and screens

1

5. Dividend

5.1 Amount

AHR has a Yearly Dividend Yield of 3.22%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 16.86, AHR's dividend is way lower than its industry peers. On top of this 80.77% of the companies listed in the same industry pay a better dividend than AHR!
Compared to an average S&P500 Dividend Yield of 2.51, AHR pays a bit more dividend than the S&P500 average.
Industry RankSector Rank
Dividend Yield 3.22%

5.2 History

AHR does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
AHR Yearly Dividends per shareAHR Yearly Dividends per shareYearly Dividends per share 2024 2025 0.2 0.4 0.6 0.8

5.3 Sustainability

The earnings of AHR are negative and hence is the payout ratio. AHR will probably not be able to sustain this dividend level.
DP-319.73%
EPS Next 2Y101.89%
EPS Next 3Y70.49%
AHR Yearly Income VS Free CF VS DividendAHR Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2021 2022 2023 2024 0 50M -50M 100M -100M

More info and screens

AMERICAN HEALTHCARE REIT INC

NYSE:AHR (4/25/2025, 8:04:00 PM)

After market: 31.11 0 (0%)

31.11

+0.03 (+0.1%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryDiversified REITs
Earnings (Last)02-27 2025-02-27/amc
Earnings (Next)05-08 2025-05-08
Inst Owners98.42%
Inst Owner Change-0.04%
Ins Owners0.82%
Ins Owner Change7.2%
Market Cap4.94B
Analysts81.67
Price Target34.55 (11.06%)
Short Float %5.21%
Short Ratio4.21
Dividend
Industry RankSector Rank
Dividend Yield 3.22%
Yearly Dividend1.08
Dividend Growth(5Y)N/A
DP-319.73%
Div Incr Years0
Div Non Decr Years0
Ex-Date03-31 2025-03-31 (0.25)
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-327.97%
Min EPS beat(2)-359.9%
Max EPS beat(2)-296.04%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.23%
Min Revenue beat(2)-0.4%
Max Revenue beat(2)6.85%
Revenue beat(4)2
Avg Revenue beat(4)1.3%
Min Revenue beat(4)-1.61%
Max Revenue beat(4)6.85%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.23%
PT rev (3m)9.72%
EPS NQ rev (1m)-30.77%
EPS NQ rev (3m)0%
EPS NY rev (1m)-5.19%
EPS NY rev (3m)37.74%
Revenue NQ rev (1m)-1.6%
Revenue NQ rev (3m)-1.6%
Revenue NY rev (1m)-1.33%
Revenue NY rev (3m)-0.8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 84.39
P/S 2.38
P/FCF 207.47
P/OCF 28.04
P/B 2.18
P/tB 2.65
EV/EBITDA 20.76
EPS(TTM)-0.27
EYN/A
EPS(NY)0.37
Fwd EY1.18%
FCF(TTM)0.15
FCFY0.48%
OCF(TTM)1.11
OCFY3.57%
SpS13.05
BVpS14.25
TBVpS11.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.84%
ROE -1.67%
ROCE 3.37%
ROIC 2.66%
ROICexc 2.71%
ROICexgc 3.04%
OM 6.61%
PM (TTM) N/A
GM 20.13%
FCFM 1.15%
ROA(3y)-1.37%
ROA(5y)N/A
ROE(3y)-4.37%
ROE(5y)N/A
ROIC(3y)1.94%
ROIC(5y)N/A
ROICexc(3y)1.97%
ROICexc(5y)N/A
ROICexgc(3y)2.22%
ROICexgc(5y)N/A
ROCE(3y)2.45%
ROCE(5y)N/A
ROICexcg growth 3Y56.38%
ROICexcg growth 5YN/A
ROICexc growth 3Y56.96%
ROICexc growth 5YN/A
OM growth 3Y31.86%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.79%
GM growth 5YN/A
F-Score7
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 0.75
Debt/FCF 71.67
Debt/EBITDA 5.4
Cap/Depr 84.99%
Cap/Sales 7.35%
Interest Coverage 1.18
Cash Conversion 55.73%
Profit Quality N/A
Current Ratio 0.68
Quick Ratio 0.68
Altman-Z 1.4
F-Score7
WACC7.53%
ROIC/WACC0.35
Cap/Depr(3y)83.56%
Cap/Depr(5y)N/A
Cap/Sales(3y)7.98%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.78%
EPS Next Y236.54%
EPS Next 2Y101.89%
EPS Next 3Y70.49%
EPS Next 5YN/A
Revenue 1Y (TTM)10.93%
Revenue growth 3Y17.32%
Revenue growth 5YN/A
Sales Q2Q%12.47%
Revenue Next Year8.62%
Revenue Next 2Y7.49%
Revenue Next 3Y9.72%
Revenue Next 5YN/A
EBIT growth 1Y78.29%
EBIT growth 3Y54.7%
EBIT growth 5YN/A
EBIT Next Year168.09%
EBIT Next 3Y45.72%
EBIT Next 5YN/A
FCF growth 1Y151.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y78.71%
OCF growth 3Y114.22%
OCF growth 5YN/A